Michael Wechsler, MD, of National Jewish Health, discusses how twice yearly depemokimab reduces exacerbation risk in patients with T2 asthma. The findings suggest twice yearly dosing may offer early ...
Type 2 (T2)-high and T2-low asthma are distinguishable by unique transcriptomic networks, but characterization of T2-low asthma remains relatively poo ...
Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, ...
Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, says Catherine Varney, DO. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...
BC, discusses how data builds payer trust, reduces prior authorization, and expands access in community oncology. In one of its most recent pilots, AON partnered with Evolent Health and a specific ...
CMS is accelerating downside risk in value-based care (VBC), even though many clinicians, practices, and health systems lack the operational and measurement infrastructure needed ...
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...
Telitacicept has the first regulatory approval for Sjögren disease (China), while global phase 3 programs aim to support ...
Contact sensitization was detected in 79.6% of hand eczema patients, with 33.3% polysensitized and 46.3% reacting to a single allergen on baseline series testing. Nickel sulfate and fragrance mix 1 ...
Rotterdam-based diagnosis (2 of oligo/anovulation, hyperandrogenism, polycystic ovarian morphology) persists, but ...
Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results